Selinexor serves as an oral selective inhibitor of nuclear export for relapsed refractory multiple myelomaSelinexor offers a new option for relapsed multiple myeloma

This narrative review explores the clinical application of selinexor, an oral selective inhibitor of nuclear export, specifically for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). The scope of the review includes an assessment of both the efficacy of the intervention and the management of associated adverse events.

The authors synthesize information regarding the use of selinexor in the RRMM population. While specific primary data points and p-values are not reported in the summary, the review highlights the clinical utility of selinexor and the necessity of managing specific adverse effects, including thrombocytopenia and gastrointestinal reactions. The review serves as a practical, evidence-based reference for clinicians to navigate the treatment landscape for these patients.

Limitations of the review include the absence of specific trial-level data in the summary and the lack of reported follow-up durations or specific outcome metrics. The clinical relevance is focused on providing a framework for the safe and effective administration of selinexor. Clinicians should note that the review synthesizes evidence from specific trials, such as STORM and BOSTON, but does not provide the raw primary data from those trials in this summary.